Pharmbio Korea
Korea - SeoulBiotechnology
Focus: Pharmbio Korea is a Seoul-based biotechnology company focused on small molecule oncology therapeutics. Limited public data restricts assessment of market position and operational scale.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
Open Jobs
0
About Pharmbio Korea
AI assessmentNot HiringNo open roles listed right now. Follow Pharmbio Korea to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthStrong
Pipeline
Late-stage
7 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Effect of Probiotic Lactobacilli (Lacidofil Cap®) for the Prevention of Antibiotic-Associated Diarrh
Antibiotics Associated ColitisClinical Trials (1)
NCT01058356Effect of Probiotic Lactobacilli (Lacidofil Cap®) for the Prevention of Antibiotic-Associated Diarrhea
N/AHelp build intelligence for Pharmbio Korea
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.